Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

Violette Allouchery; Ludivine Beaussire; Anne Perdrix; David Sefrioui; Laetitia Augusto; Cécile Guillemet; Nasrin Sarafan-Vasseur; Frédéric Di Fiore; Florian Clatot

doi:10.1186/s13058-018-0968-0

Journal articles

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

Violette Allouchery ¹ Ludivine Beaussire ² Anne Perdrix ^{2, 1} David Sefrioui ² Laetitia Augusto ¹ Cécile Guillemet ^{3, 1} Nasrin Sarafan-Vasseur ² Frédéric Di Fiore ^{4, 1, 2} Florian Clatot ^{2, 1}

1 CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen

2 GPMCND - Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques

3 Service d'Oncologie Médicale

4 Département d'oncologie médicale [Rouen]

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Cancer

Complete list of metadata

https://hal-normandie-univ.archives-ouvertes.fr/hal-02352867
Contributor : Florian CLATOT Connect in order to contact the contributor
Submitted on : Thursday, November 7, 2019 - 9:30:51 AM
Last modification on : Friday, March 11, 2022 - 6:14:02 PM

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

Links full text

Identifiers

Collections

Citation

Export

Metrics

27

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

Links full text

Identifiers

Collections

Citation

Export

Share

Metrics

27